Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04747613

Active Not RecruitingPhase 3

Sponsor: Novartis Pharmaceuticals

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Iptacopan

Countries: United States, Brazil, China, Czechia, France, Germany, Italy, Japan

This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion criteria:

* Male and female participants ≥ 18 years of age with a diagnosis of PNH who have completed the treatment extension period (without tapering down) of Phase II iptacopan studies (CLNP023X2204, CLNP023X2201), Period 4 of LFG316X2201 or Phase III (CLNP023C12302 and CLNP023C12301) clinical studies at the time point of enrollment visit in this roll over extension.
* Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections
* Per investigator's clinical judgement benefit from continued treatment with iptacopan and has been clinically stable on iptacopan monotherapy for at least 3 months

Exclusion Criteria:

* Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
* History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae
* History of hematopoietic stem cell transplantation

Other protocol-defined inclusion/exclusion criteria may apply.
Locations (60)
  • Duarte, California, United States
  • Duarte, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Orange, California, United States
  • Miami Lakes, Florida, United States
  • Augusta, Georgia, United States
  • Augusta, Georgia, United States
  • The Bronx, New York, United States
  • Cleveland, Ohio, United States
  • Greenville, South Carolina, United States
  • Santo André, São Paulo, Brazil
  • São Paulo, São Paulo, Brazil
  • Beijing, China
  • Tianjin, China
  • Tianjin, China
  • Ostrava, Poruba, Czechia
  • Brno, Czechia
  • Lille, France
  • Nantes, France
  • Nice, France
  • Paris, France
  • Toulouse, France
  • Dresden, Saxony, Germany
  • Aachen, Germany
  • Essen, Germany
  • Hamburg, Germany
  • Riesa, Germany
  • Ulm, Germany
  • Ascoli Piceno, AP, Italy
  • + 30 more on CT.gov